Table 1.
Patient Characteristics.
| Group A(later GJG administration) | Group B (prophylactic GJG administration) | P value | |
|---|---|---|---|
| Variables | n = 26 | n = 27 | |
| Age (years, mean ± SD) | 58.7 ± 11.4 | 60.4 ± 8.9 | .545 |
| BMI (kg/m2, mean ± SD) | 22.6 ± 0.6 | 23.4 ± 0.3 | .731 |
| BSA (m 2 , mean ± SD) | 1.53 ± 0.13 | 1.54 ± 0.13 | .754 |
| Menopausal status | |||
| Premenopausal | 7 (26.9%) | 6 (21.4%) | .757 |
| Menopausal | 19 (73.1%) | 21 (78.6%) | |
| Performance status | |||
| 0 | 26 (100%) | 27 (100%) | - |
| Chemotherapy cycle | |||
| 1 | 1 (3.8%) | 1 (3.7%) | .268 |
| 2 | 2 (7.7%) | 1 (3.7%) | |
| 3 | 0 | 2 (7.4%) | |
| 4 | 0 | 1 (3.7%) | |
| 5 | 3 (11.5%) | 0 | |
| 6 | 20 (76.9%) | 22 (81.5%) | |
| Time to start GJG | |||
| Not administered | 8 (30.8%) | ||
| 1 cycle | 7 (26.9%) | ||
| 2 cycles | 6 (23.1%) | ||
| 3 cycles | 3 (11.5%) | ||
| 4 cycles | 0 | ||
| 5 cycles | 1 (3.8%) | ||
| 6 cycles | 1 (3.8%) | ||
| Total dose of paclitaxel (mg, mean ± SD) | 1390.7 ± 397.8 | 1391.3 ± 388.8 | .995 |
| Total dose of carboplatin (mg, mean ± SD) | 3010.8 ± 1062.1 | 3011.1 ± 860.6 | .999 |
Abbreviations: BMI, body mass index; BSA, body surface area; GJG, Goshajinkigan; SD, standard deviation.